Posted by By AHRA Staff
December 2010–Every month, we post an industry and management related situation to you, our members. You are then encouraged to share your thoughts on how you would resolve the issue. Be sure to check out others’ responses and join the discussion.
This month, we’re taking a look at a dilemma that many of you may have experienced recently. Tell us what you did do:
The last year has been a difficult one for the many in the cardiac molecular imaging community (nuclear medicine), as they faced the shortage of Technetium-99m (Tc-99m). As a result, radiopharmacies across the country were forced to ration doses of Tc-99m for cardiac imaging in nuclear medicine. Now that the Chalk River Nuclear Reactor is back on commission, the imaging community now has relief in sight and what it appears to be the end of the Tc-99m shortage. How did you cope with the shortage? What impact did the shortage have on your facility? What is your prognosis on the damage done (if any)?
Have a suggestion for What Would You Do? Email Associate Editor Emily Doutre at edoutre@ahraonline.org.
LINK 